TY - GEN
T1 - Piloting Photoplethysmographic Smartphone-Based Atrial Fibrillation Screening in Austria
T2 - Joint Annual Conference of the Austrian (ÖGBMT), German (VDE DGBMT) and Swiss (SSBE) Societies for Biomedical Engineering (9–11 September 2025, Muttenz/Basel, Switzerland)
AU - Baumgartner, Martin
AU - Hofhansel, Lena
AU - Aumayer, Helen
AU - Woodford, Melanie
AU - Müllner-Rieder, Markus
AU - Edegger, Kurt
AU - Schreinlechner, Michael
AU - Pavluk, Daniel
AU - Scherr, Daniel
AU - Manninger-Wünscher, Martin
AU - Reinstadler, Sebastian
AU - Bauer, Axel
AU - Schreier, Günter
A2 - Hayn, Dieter
A2 - Hauseisen, Jens
PY - 2025/9/12
Y1 - 2025/9/12
N2 - Atrial fibrillation (AF), the most common sustained arrhythmia, affects over 59 million people worldwide and carries a high risk of serious complications such as stroke. However, AF often goes undiagnosed, leaving many patients untreated. Photoplethysmography (PPG) is a non-invasive method for AF detection, accessible via wearables or smartphone apps. This paper presents two integrated smartphone apps—one for user registration and one for PPG-based AF screening—developed for use in a large-scale, prospective, randomised, centreless clinical trial. The screening app incorporates third-party AF detection Software Development Kits (SDKs) which are certified as class IIa medical devices. A pilot study confirmed the technical feasibility of the approach and identified minor areas for improvement. These insights will guide app refinement ahead of a nationwide AF screening study in Austria, planned for 2026.
AB - Atrial fibrillation (AF), the most common sustained arrhythmia, affects over 59 million people worldwide and carries a high risk of serious complications such as stroke. However, AF often goes undiagnosed, leaving many patients untreated. Photoplethysmography (PPG) is a non-invasive method for AF detection, accessible via wearables or smartphone apps. This paper presents two integrated smartphone apps—one for user registration and one for PPG-based AF screening—developed for use in a large-scale, prospective, randomised, centreless clinical trial. The screening app incorporates third-party AF detection Software Development Kits (SDKs) which are certified as class IIa medical devices. A pilot study confirmed the technical feasibility of the approach and identified minor areas for improvement. These insights will guide app refinement ahead of a nationwide AF screening study in Austria, planned for 2026.
KW - Digital Health
KW - Mobile Health
KW - mHealth
KW - Atrial Fibrillation
KW - Photoplethysmography
U2 - 10.1515/cdbme-2025-0164
DO - 10.1515/cdbme-2025-0164
M3 - Conference Proceedings with Oral Presentation
VL - 11
T3 - Current Directions in Biomedical Engineering
SP - 250
EP - 253
BT - Current Directions in Biomedical Engineering
PB - de Gruyter
Y2 - 9 September 2025 through 11 November 2025
ER -